Form 4: Astrana Health Director Weili Dai Granted 6,449 Restricted Shares

Astrana Health, Inc. Director Weili Dai was granted 6,449 shares of common stock as restricted stock, aligning her interests with shareholders.

Summary

• Weili Dai, a Director of Astrana Health, Inc. (ASTH), acquired 6,449 shares of the company's common stock.
• The acquisition was a grant of restricted shares under the Issuer's 2024 Equity Incentive Plan.
• These restricted shares will vest on the earlier of June 11, 2026, or the date of the Issuer's 2026 annual meeting of stockholders.
• Following this transaction, Weili Dai beneficially owns a total of 13,663 shares of Astrana Health common stock.
• The transaction date was June 11, 2025, and the filing was made on June 13, 2025.

Sentiment

Score: 6

Explanation: The document reports a routine grant of restricted stock to a director, which is a positive for aligning interests but does not indicate significant new financial performance or strategic shifts.

Positives

• The grant of restricted stock to Director Weili Dai aligns her long-term interests with those of the company's shareholders.
• The transaction demonstrates continued use of the company's 2024 Equity Incentive Plan to incentivize key personnel.

Negatives

• No negative aspects are indicated by this routine insider transaction disclosure.

Risks

• This Form 4 filing does not disclose specific risks to the company's operations or financial health.

Future Outlook

The granted restricted shares are subject to a future vesting schedule, indicating a commitment to long-term retention and performance alignment, with vesting expected by June 11, 2026, or the 2026 annual meeting.

Industry Context

This is a standard Form 4 filing, which is a routine disclosure for insider transactions in publicly traded companies. Such grants are common mechanisms for executive and director compensation across various industries, aiming to align leadership incentives with shareholder value.

Corporate Governance

Related Party Transactions

• The grant of restricted shares to Director Weili Dai constitutes a related party transaction, as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant of restricted stock to a director helps align the director's financial interests with those of the shareholders, potentially encouraging decisions that enhance long-term shareholder value.

Next Steps

• Vesting of the 6,449 restricted shares on the earlier of June 11, 2026, or the date of the Issuer's 2026 annual meeting of stockholders.

Key Dates

Keywords

Astrana Health, ASTH, Form 4, Insider Transaction, Restricted Stock Grant, Director Compensation, Equity Incentive Plan, Weili Dai, Stock Ownership